Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Crohn Disease

• Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.
• Fluorescence Imaging of Adalimumab-680LT in Inflammatory Bowel Disease
• Subcutaneous Infliximab After A Previous Intravenous Dose Optimization
• Hyperbaric Oxygen Therapy for Perianal Fistulizing Crohn's Disease Not Responsive or Intolerant to Conventional Care: HYPNOTIC Pilot Study
• A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
• Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative Colitis
• Efficacy and Safety of Formulation Switching Between SC Infliximab and IV Infliximab in Patients With CD
• A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
• inDuctIon tREatment With subCuTaneous Infliximab for Crohn's Disease
• Study of Tolerability, Safety, and Pharmacokinetics of ZL-82 in Healthy Adult Subjects.
• Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease
• TDM-based Infliximab Treatment for Active Perianal Fistulizing Crohn's Disease
• A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
• A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
• A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
• RVT-3101 for the Treatment of Moderate to Severe Active Crohn's Disease
• Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients
• A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease
• A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease
• HLADQA1*05 Genotype and the Efficacy of Treatment With Infliximab in Chinese Population Crohn's Disease
• Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATH-063 in Healthy Subjects
• A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection
• Quantitative Fluorescence Molecular Imaging of Ustekinumab-800CW to Elucidate the Drug Distribution Throughout Inflamed Tissue in Crohn's Disease and Psoriasis.
• VTX958 for the Treatment of Moderately to Severely Active Crohn's Disease
• A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
• Precise Infliximab Exposure and Pharmacodynamic Control
• LMT503 First-in-human SAD, MAD, and FE Study
• A Study of Human TH-SC01 Cell Injection for Treating Perianal Fistulas in Patients With Crohn's Disease
• High Dose Steroid to Treat Flares in Inflammatory Bowel Disease
• Medical Treatment Versus Surgery in Stricturing Small Bowel Crohn's Disease
• Stem Cells for the Treatment of Pouchitis
• Pharmacokinetic Infliximab Data in Pediatric Crohn's Disease
• EXL01 in the Maintenance of Steroid-induced Clinical Response/Remission in Participants With Mild to Moderate Crohn's Disease
• Clinical Trial to Evaluate if the Laparoscopic Administration of Cells Derived From the Fatty Tissue Can Improve the Inflammatory Stenosis in Patient With Crohn's Disease
• A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease (AMAY)
• The Effects of Intraoperative Esketamine on Postoperative Pain and Mood in Patients With Inflammatory Bowel Disease
• A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
• Study to Evaluate the Efficacy and Safety of PF-06480605 in Adult Participants With Moderate to Severe Crohn's Disease
• A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy
• A Study of Vedolizumab in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)
• Transversus Abdominis Plane Blocks With and Without Dexamethasone
• A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
• An Open-Label Extension and Long-term Efficacy and Safety Monitoring Study of Patients With Crohn's Disease Previously Included in the Loss of RESponse to Ustekinumab Treated by Dose Escalation Study
• Exclusion Diet vs corticosteroIds in patientS With activE Crohn's Disease
• A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
• A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
• The Nordic IBD Treatment Strategy Trial
• Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biological Therapy
• A Phase I Study of ExoFlo, an ex Vivo Culture-expanded Adult Allogeneic Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Isolate Product, for the Treatment of Medically Refractory Crohn's Disease
• SAVES-IBD: Safety & Efficacy of Aspirin vs. Standard of Care for VTE Prophylaxis After IBD Surgery
• A Long-term Extension Study of Ustekinumab in Pediatric Participants
• Assessment of the Safety, Tolerability, and Pharmacokinetic of HM201
• Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency
• Study of Ossium Mesenchymal Stem Cells for the Treatment of Pouch Fistulas in the Setting of Crohn's Disease
• Management of Moderate POstoperative Recurrence in Crohn's Disease: a randoMizEd contROLled Trial of Therapeutic Escalation, the POMEROL Trial. (POMEROL)
• A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease
• Safety and Efficacy of Oral BT-11 in Crohn's Disease Patients With Moderate to Severe Disease
• Evaluation of the Response of Itraconazole and Terbinafine Therapy in Subjects With Crohn's Disease
• Combined Immunosuppression for Pediatric Crohn's Disease
• Comparison of Azathioprine to Methotrexate in Combination Therapy With Adalimumab in Crohn's Disease: an Open-label Randomized Controlled Trial
• The Efficacy and Safety of Oral Etrasimod as Therapy for Moderately to Severely Active Crohn's Disease
• A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease
• A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease
• A Phase 2a Safety and Efficacy Open-Label Study of PRA023 in Subjects With Moderately to Severely Active Crohn's Disease
• A Study to Test Whether Spesolimab Helps People With Crohn's Disease Who Have Symptoms of Bowel Obstruction
• Fecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal
• A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease
• Personalized Infliximab Induction Strategy With Model-informed Dosing in Patients With Crohn's Disease
• The MIRO II Study: Microbial Restoration in Inflammatory Bowel Diseases
• Pilot Study of Posaconazole in Crohn's Disease
• A Study of TH-SC01 for Treating Complex Perianal Fistula in Perianal Crohn's Disease.
• Exclusive Enteral Nutrition in Patients With Ileocaecal Crohn's Disease
• Efficacy and Safety of Vedolizumab in Biologic-naïve Korean Patients With Moderate to Severe Inflammatory Bowel Disease
• A Study to Evaluate the Long-term Safety and Efficacy of BMS-986165 in Participants With Crohn's Disease or Ulcerative Colitis
• Seeded Cells on Matrix Plug Treating Crohn's Perianal Fistulas
• A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
• The OPTIMIZE Trial
• Vitamin D Regulation of Gut Specific B Cells and Antibodies Targeting Gut Bacteria in Inflammatory Bowel Disease
• A Study of Vedolizumab in People With Ulcerative Colitis and Crohn's Disease
• Study of Mesenchymal Stem Cells for Pediatric Perianal Fistulizing Crohn's Disease
• Stelara and Diet Trial for Crohn"s Disease
• A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease
• N-3 Polyunsaturated Fatty Acids Prevent Postoperative Recurrence of Crohn's Disease
• A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease
• Safety and Efficacy of Artesunate & Curcumin in Crohn's Disease
• Anastomotic Leakage and Value Of Indocyanine Green in Decreasing Leakage Rates
• Flagyl Microbiome in Crohn's Disease
• A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
• A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease
• A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease
• Induction Optimization With Stelara for Crohn's Disease
• A Phase 2 Clinical Trial: Xanthohumol Metabolism and Signature (XMaS) in Crohn's Disease
• Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis
• Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
• Mesenchymal Stem Cells for the Treatment of Rectovaginal Fistulas in Participants With Crohn's Disease
• Study of Mesenchymal Stem Cells for the Treatment of Ileal Pouch Fistula's in Participants With Crohn's Disease
• Mesenchymal Stem Cells for the Treatment of Perianal Fistulizing Crohn's Disease
• USTekinumab in Fistulising Perianal Crohn's Disease (USTAP)
• Reduce Crohn's-Associated Diarrhea With Sodium Channel Therapy
• A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
• A Study to Test Long-term Treatment With Spesolimab in Patients With Fistulising Crohn's Disease Who Took Part in Previous Trials
• Exploring the Effects of Vitamin D Supplementation on the Chronic Course of Patients With Crohn's Disease With Vitamin D Deficiency
• Exploring the Effects of Caltrate Supplement on the Chronic Course of Crohn's Disease Patients With Vitamin D Deficiency
• LOW DOSE IL-2 FOR THE TREATMENT OF CROHN'S DISEASE
• A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
• Rifaximin in Patients With Diabetic Gastroparesis
• Loss of RESponse to Ustekinumab Treated by Dose Escalation
• The Effect of Oral Polymeric Diet Enriched With TGF-beta 2 (Modulen) on Clinical Response and Mucosal Healing in Adult Patients With Newly Diagnosed Crohn's Disease
• A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
• Stem Cell Transplantation in Crohn's Disease
• Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)
• A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease
• Extracorporeal Photopheresis of Patients With Crohn's Disease Using 5-aminolevulinic Acid
• A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)
• Effect of the Exclusive Enteral Nutrition Combined With Azathioprine for Remission of Crohn's Diseases After Surgery
• Autologous Transplant Targeted Against Crohn's
• Study to Evaluate Safety, Tolerability and Efficacy of GSK2330811 in Crohn's Disease
• the Effect of Vitamin D in Crohn's Disease
• Loss of Response of Adalimumab Biosimilar vs Adalimumab Original, in Inflammatory Bowel Disease.
• NIR FME of Labelled Vedolizumab to Elucidate the Mechanism of Action and Predicting Response in IBD Patients.
• A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease
• Mesenchymal Stem Cells for the Treatment of Pouch Fistulas in Crohn's
• A Phase 2a Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol as a Steroid-sparing Therapy in Steroid-dependent Crohn's Disease Patients
• Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS
• The Vitamin D in Pediatric Crohn's Disease ( ViDiPeC-2 )
• Study to Evaluate Safety, Tolerability and Efficacy of Oral B-FAHF-2 in Mild-to-Moderate Crohn's Disease
• Oral Administration of MB-102 Versus Dual Sugar Testing for Gut Permeability
• Open-label Extension Study of Brazikumab in Crohn's Disease
• Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19
• TAK-018 for Prevention of the Recurrence of Postoperative Crohn's Disease (CD)
• Postoperative Extended Venous Thromboprophylaxis in Inflammatory Bowel Disease
• A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
• Control Crohn Safe Trial
• Safety Evaluation of ABX464 in Patients With Moderate to Severe Active Crohn's Disease
• The Effects of Parenteral ω-3 Polyunsaturated Fatty Acid on Postoperative Complications of Patients With Crohn's Disease
• Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease
• Safety, Tolerability, and Pharmacokinetics of Oral BT-11 in Healthy Adult Male and Female Volunteers
• Phase 2a Study of PRV-6527 in Subjects With Moderately to Severely Active Crohn's Disease
• Efficacy and Safety of Oral OPS-2071 in Participants With Crohn's Disease Showing Symptoms of Active Inflammation
• Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
• Exclusive Enteral Nutrition and Corticosteroids Therapy in Crohn's Disease (EENCD)
• A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease
• An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease
• A Study Testing How BI 655130 Works in Patients With Fistulizing Crohn's Disease
• A Study of E6011 in Participants With Active Crohn's Disease
• Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®)
• Identification by Cytometry by Mass of Predictive Immunological Profiles of Answer to Treatmentby Biotherapics for Patients With Crohn's Disease
• A Study of a FimH Blocker, EB8018, in Crohn's Disease Patients
• A Clinical Trial of Antibody GSK1070806 in the Treatment of Patients With Moderate to Severe Crohn's Disease
• A Phase II Study in Patients With Moderate to Severe Active Crohn's Disease
• Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease
• An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease
• Efficacy and Safety of TD-1473 in Crohn's Disease
• Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)
• Contribution of a Non Medicamentous Approach by Hypnosis on Quality of Life in Crohn Disease
• An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease
• HMPL004-6599 Phase I Dose-escalating Study
• 5-HTP in Patients With IBD in Clinical and Biologic Remission:Effect on Fatigue Scores
• Diagnostic Validity of [18F]FSPG PET for the Assessment of Disease Activity in Inflammatory Bowel Disease
• A Multicentre Study on Rifaximin in Post-operative Endoscopic Crohn's Disease Recurrence Prevention
• A Phase I Study Of Etrolizumab Followed By Open-Label Extension And Safety Monitoring In Pediatric Patients With Moderate To Severe Ulcerative Colitis Or Moderate To Severe Crohn's Disease
• Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease
• An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
• Cannabidiol Usage as an Adjunct Therapy for Crohn's Disease
• A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
• A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease
• Pediatric MSC-AFP Sub-study for Crohn's Fistula
• Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
• Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
• Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic Function
• Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease
• The Therapy Effect of Azathioprine Initial or 14 Weeks After Combined With Infliximab on CD
• A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis
• Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately t
• A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies
• A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy
• A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
• A Study to Determine the Pharmacokinetics (PK) of Single Intravenous (IV) Dose of Vedolizumab 300 Milligram (mg) in Healthy Adult Chinese Participants
• Changing the coUrse of cRohn's Disease With an Early Use of Adalimumab
• A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
• Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn's Disease (CD)
• Ultrasound Evaluation of Crohn's Disease
• Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease
• Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic Factors
• Stricture Definition and Treatment (STRIDENT) Drug Therapy Study
• Stem Cell Coated Fistula Plug in Patients With Crohn's RVF
• Autologous Stem Cell Transplant for Crohn's Disease
• Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)
• Effectiveness of Rifaximin on Preventing Postoperative Recurrence in Crohn's Disease
• Effectiveness of Rifaximin Combined With Thiopurine on Preventing Postoperative Recurrence in Crohn's Disease
• Treg Immunotherapy in Crohn's Disease
• Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease
• An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab
• High Dose Interval Vitamin D Supplementation in Patients With IBD Receiving Remicade
• Tolerability, Pharmacokinetics, and Efficacy of APD371 in Participants With Crohn's Disease Experiencing Abdominal Pain
• Defining Predictors of RT Response to Vedolizumab in IBD
• Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)
• Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab
• A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
• A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
• A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment
• Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease
• Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)
• A First Time in Human Study in Healthy Volunteers and Patients
• Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease
• Thalidomide Results in Diminished Ovarian Reserve in Reproductive Age Female IBD Patients
• GIS-SUSANTI-TNF-2015 (Anti-TNF Discontinuation )
• A Six Week Efficacy, Safety and Tolerability Study of V565 in Crohn's Disease
• A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease
• A Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
• Induced Adult Refractory Active Crohn's Disease Clinical Relieving by Using Thalidomide
• Synergistic Effect of Vedolizumab and Pentoxifylline
• Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease
• Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease
• Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or Crohn's Disease
• Fecal Microbiota Transplantation Improves Nutritional State of Patients With Crohn's Disease
• A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease
• Efficacy of Exclusive Enteral Nutrition in Adult Active Crohn's Disease
• Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease
• Comparing the Quality of Life of Terminal Ileitis Patients With Crohn's Disease Treated With Anti-TNF or Surgical Resection
• BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity
• Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases
• Reduce Risk for Crohn's Disease Patients
• Vedolizumab Post Op Study
• Effectiveness of Vedolizumab in CD Patients Naïve to Anti-TNF
• Prucalopride Prior to Small Bowel Capsule Endoscopy
• Efficacy of CROWN in Repair and Maintenance of the Intestinal Mucosa in Patients With CD Receiving Anti-TNF Therapy
• A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease
• Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy
• The Efficacy of Topical Mesalazine Sustained-Release Tablets in Crohn's Disease Patients With Oral Ulcer
• Value of Pharmacokinetic Assays in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's Disease
• Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease
• Triple Combination Therapy in High Risk Crohn's Disease (CD)
• Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study
• A Safety Study of Intravenously Administered UTTR1147A in Healthy Volunteers (HVs), Participants With Ulcerative Colitis (UC), and Participants With Crohn's Disease (CD)
• Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Disease
• Pharmacodynamic and Clinical Outcome Study of Mongersen in Patients With Crohn's Disease
• Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD
• OTIS Vedolizumab Pregnancy Exposure Registry
• AlloGeneic Human Mesenchymal Stem Cells (hMSC) in PAtients With FistuLizing Crohn's Disease Via PErifistula iNjEctions (GALENE)
• Autologous Stem Cell Transplant for Refractory Crohn's Disease
• To Evaluate the Efficacy and Safety of Rapamycin for Crohn's Disease-related Stricture
• Entyvio (Vedolizumab) Long Term Safety Study
• A Study to Evaluate Efficacy, of Early Versus Late Use of Vedolizumab in Crohn's Disease: the LOVE-CD Study
• A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease
• Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease
• A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease
• Evaluation of Adherent Invasive E. Coli Eradication in Adult Crohn Disease
• Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease
• Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD)
• Does Clinical Response Correlate With Serum Certolizumab Levels?
• Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease
• Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease
• Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease
• Effect of Prebiotic FOS on Intestinal Abundance of Faecalibacterium Prausnitzii in Patients With Crohn´s Disease
• Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel Disease
• Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)
• A Comparison of Ultrasound Guided Transversus Abdominis Plane Nerve Block Techniques
• Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)
• The Efficiency of MSC in Refractory Crohn's Disease
• Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease
• TOPIT; Trough Level Optimized Pediatric Inflammatory Bowel Disease Therapy: A Multicenter Study Comparing Effectiveness of Trough Level Optimized Infliximab Maintenance Therapy With Standard Dosing Regimen of Pediatric Patients With Crohn's Disease
• An Innovative Treatment for Fistula-in-ano in Crohn Disease : Local Micro Reinjection of Autologous Fat and SVF
• Top-down Infliximab Study in Kids With Crohn's Disease
• A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease
• Thalidomide in Treating Crohn's Disease
• A Pilot Study of FFP104 in Subjects With Crohn's Disease
• The Impact of 6MP Metabolite Levels on Infliximab Pharmacokinetics and Anti-infliximab Antibodies in Crohn's Disease
• "Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial"
• Adalimumab Trough Concentrations in Crohn's Disease: A Pilot Pharmacokinetic Study
• Umbilical Cord Mesenchymal Stem Cell Treatment for Crohn's Disease
• Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease
• Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator
• Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease
• Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144
• A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease
• Corticosteroid Dosage for Crohn's Disease Flare
• Extension Study of MT-1303 in Subjects With Crohn's Disease
• Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease
• A Randomized, Double-blind, Study to Explore the Effect of GED-0301 in Subjects With Active Crohn's Disease
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intoleran
• Immune Modulation by Parenteral Fish Oil in Patients With Crohn's Disease
• Standardized Fecal Microbiota Transplantation for Inflammatory Bowel Disease
• Therapeutic Optimization Study Based on MR Enterocolonography in Patients With Crohn's Disease
• Study Evaluating Ovasave, an Autologous Cell Therapy, in Patients With Active Crohn's Disease
• Corticosteroids With Vedolizumab in Crohn's Disease
• The Efficacy of Denosumab in Active Crohn's Disease
• Safety Study of P28GST Treatment in Crohn's Disease Patients
• Fecal Microbial Transplant in Pediatric Crohn's Disease
• Salvage Therapy With High/Low Methotrexate for Loss of Response to Infliximab Dose Escalation
• Pediatric Crohn's Disease AdalImumab Level-based Optimization Treatment (PAILOT) Trial
• Curcumin Associated With Thiopurin in the Prevention of Post-op Recurrence in Crohn Disease
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 3 Subcutaneous and 1 Intravenous Dose of E6011 in Subjects With Active Crohn's Disease
• Azathioprine in the Prevention of Ileal Crohn's Disease Postoperative Recurrence.
• One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease
• One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease
• Dose Finding Study of BIRB 796 BS in Patients With Moderate to Severe Crohn's Disease
• Trial of High Dose Vitamin D in Patient's With Crohn's Disease
• The Vitamin D in Pediatric Crohn's Disease
• Oral Administration of AlequelTM for Patients With Inflammatory Bowel Disease (IBD)
• Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115
• A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy
• Effect of Soluble Dietary Fiber on Bacterial Translocation in Crohn's Disease
• The NOR-SWITCH Study
• Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Study of MT-1303 in Subjects With Crohn's Disease
• Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease
• Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease
• Contrast-Enhanced Ultrasound in Human Crohn's Disease
• Regulatory T-cells and Crohn's Disease
• Effects of Enteral Nutrition and Corticosteroid on Intestinal Flora in Induction Remission of Crohn Disease in Adult
• Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease
• Efficacy and Safety Study of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction Remission
• A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's Disease
• Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease
• Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, Moderate-to-severe Crohn's Disease.
• The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease
• Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate
• Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases
• Adalimumab Intralesional in Intestinal Strictures of Crohn's Disease Patients
• Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease
• Stem Cell Fistula Plug in Perianal Crohn's Disease
• Anti TNF α Improves Endothelial Dysfunction in IBD Patients
• Infliximab Top-down in Pediatric Crohn
• High-dose Cyclophosphamide for Severe Refractory Crohn Disease
• Single and Repeat Dose Pharmacokinetic Study of GSK1605786 in Healthy Chinese Subjects
• Combined THC and CBD Drops for Treatment of Crohn's Disease
• The Efficacy of Enteral Nutrition in Fill of the Treatment Blank Period of the Postoperative Maintain Remission Medication for Crohn's Disease (CD)
• Oxidative Stress and Inflammation Caused by Intravenous Iron in Crohn's Disease Patients With Iron Deficiency Anemia
• Efficacy Study of Tripterygium Glycoside Combined With Enteral Nutrition in the Treatment of Crohn's Disease for Induction Remission
• Cimzia Versus Cimzia Plus Azathioprine in the Treatment of Active Crohn's Disease
• Discontinuation of Infliximab Therapy in Patients With Crohn's Disease During Sustained Complete Remission
• Low Dose Naltrexone in Symptomatic Inflammatory Bowel Disease
• Safety and Treatment Effect of QBECO in Moderate to Severe Crohn's Disease
• A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)
• Comparison of 2 Immunomodulator Withdrawal Schemes for Infliximab Monotherapy in Active Pediatric Crohn's Disease After Thiopurine Failure
• Standardized Fecal Microbiota Transplantation for Crohn&Apos;s Diseases
• Antibiotics and Hydroxychloroquine in Crohn's
• A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease
• The Effect of Probiotics on Exacerbation of Inflammatory Bowel Disease Exacerbation (Crohn's Disease)
• Efficacy and Safety of Top-down Therapy in Pediatric Crohn's Disease
• A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease
• Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.
• Cimzia Versus Mesalamine for Crohn's Recurrence
• Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease
• Bioavailability of Vitamin D in Children and Adolescents With Crohn's Disease
• Calprotectin-Directed Humira® Maintenance Therapy (CADHUM)
• Expression of TIM-3 and Correlation With Disease Activity in Pediatric Crohn's Disease With Anti TNF-α Therapy
• Growth Hormone and Exclusion Diet Therapy in Juvenile Crohn's Disease
• A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease
• A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pedi
• Adalimumab for the Management of Post-operative Crohn's Disease (CD)
• Randomized, Double-blind, Placebo-controlled Study in Patients With Fistulizing Crohn's Disease
• Japanese Phase I of GSK1605786
• Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease
• EUS Evaluation of Perianal and Peri-rectal Fistulizing Crohn's Disease With CERTOLIZUMAB Treatment
• Clinical Study of TA-650 in Pediatric Patients With Crohn's Disease
• Crohn's Allogeneic Transplant Study
• Adalimumab on Preventing Post-chirurgic Recurrence on Crohn´s Disease
• Assessment of Mucosal Activity to Improve the Prognosis of Patients With Crohn's Disease Treated With Immunosuppressants
• Efficacy and Safety of Two Regimens of Maintenance Therapy in Children With Crohn Disease
• Adalimumab-psoriasis and Small Bowel Lesions
• An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
• L-carnitine to Treat Fatigue Associated With Crohn's Disease
• Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan
• Safety and Treatment Outcome Study of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects With Treatment-resistant Crohn's Disease
• Efficacy Study of Pneumococcal Vaccination in Crohn's Disease
• A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects
• A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease
• Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease
• Safety and Maintenance Study of Entocort for Children With Crohn's Disease
• Safety Study of Entocort for Children With Crohn's Disease
• A Safety and Efficacy Study of BLI-1300 Ointment in Symptomatic Perianal Crohn's Disease
• Study Investigating Tailored Treatment With Infliximab for Active Crohn's Disease
• Understanding the Relationship Between Infliximab Levels to Clinical Response of Remicade in Crohn's Disease
• Open Label Extension Study to Protocol C2/13/DR-6MP-02
• The Safety And Efficacy Of Maintenance Therapy With CP-690,550
• A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
• A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease
• Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFs
• Safety and Efficacy of Adipose-Derived Stem Cells to Treat Complex Perianal Fistulas Patients With Crohn's Disease
• Study to Assess the Safety and Efficacy of Expanded Allogenic Adipose-derived Stem Cells (eASCs) (Cx601), for Treatment of Complex Perianal Fistulas in Perianal Crohn's Disease.
• A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)
• A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
• A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
• A Phase II Efficacy Study in Fistulizing Crohn's Disease Patients
• Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (AEGIS-2)
• Biomarkers of Intestinal Mucosal Healing in Crohn's Disease (P08143)
• Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD)
• A Study of TRK-170 for the Treatment of Crohn's Disease
• Switching From Adalimumab to Infliximab
• Open-Label Extension Study of GSK1605786A
• GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
• A Study to Assess Efficacy, Safety and Tolerability of the Anti-IL-13 Monoclonal Antibody QAX576 in the Treatment of Perinanal Fistulas in Patients Suffering From Crohn's Disease
• A Study To Monitor Long-Term Treatment With PF-00547659
• Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.
• A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
• Trichuris Suis Ova (TSO) Suspension Versus Placebo in Active Crohn's Disease
• A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease
• Intra-erythrocyte Dexamethasone Versus Placebo in Patients With Steroid-dependent Crohn's Disease
• Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease
• Safety and Tolerability of FITC-Adalimumab Administration During Confocal Laser Endomicroscopy of the Gut
• Infliximab, Regulatory T Cells, IL2 and Crohn's Disease
• Drug-Disease Interaction in Crohn's Disease
• Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects
• Chondroitin Sulfate for Crohn's Disease
• Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease
• Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
• Topical Tacrolimus 0.1% Ointment For Treatment Of Cutaneous Crohn's Disease
• Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
• Observational Study of Disease Severity in Participants Diagnosed With Crohn's Disease and Long Term Impact of Treatment Strategies in Participants With Moderate to Severe Crohn's Disease (Protocol P06484)
• Risedronate Therapy in the Treatment of Low Bone Mineral Density in Crohn's Disease
• Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease
• Colesevelam for the Treatment of Bile Acid Malabsorption in Patients With Crohn's Disease
• Safety Study in Subjects With Crohn's Disease
• A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
• Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol
• A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
• AMG 827 in Subjects With Moderate to Severe Crohn's Disease
• Small Bowel Mucosal Healing Induced by Adalimumab in Crohn's Disease Patients as Assessed by Capsule Endoscopy
• A Study to Assess the Relative Bioavailability of Four New Formulations of GSK1605786 in Healthy Subjects
• Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia
• Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease
• An Australian Study of Mesenchymal Stromal Cells for Crohn's Disease
• 9 mg Budesonide Once Daily (OD) Versus 3 mg Budesonide Three Times Daily (TID) in Active Crohn's Disease
• Assessment of Small Bowel Healing in Crohn's Disease Patients Treated With Cimzia Using Wireless Capsule Endoscopy
• Vitamin D Supplementation as Non-toxic Immunomodulation in Children With Crohn's Disease
• Cannabis for Inflammatory Bowel Disease
• Cannabidiol for Inflammatory Bowel Disease
• Efficacy Study of T2 Versus AZA to Maintain Clinical and Endoscopic Remission in Postoperative Crohn's Disease
• The Effect of Adalimumab on the Bone Microstructure in Crohn's Disease (CD) Patients
• An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's Disease
• Allogenic Stem Cells Derived From Lipoaspirates for the Treatment of Recto-vaginal Fistulas Associated to Crohn's Disease (ALOREVA)
• A Dose-finding and Confirmatory Trial of OPC-6535 in Patients With Active Crohn's Disease
• Comparison Azathioprine to Mesalazine for the Prevention of Postoperative Recurrence in the Crohn Disease
• Single Ascending Dose Study of Oral CPSI-2364 (Semapimod)
• Preventing Postoperative Relapse in Crohn's Disease Patients at Risk: Azathioprine Versus Mesalazine
• The Use of Certolizumab Pegol for Treatment of Active Crohn's Disease in Children and Adolescents
• Curcumin in Pediatric Inflammatory Bowel Disease
• A Study With Pentasa in Patients With Active Crohn's Disease
• SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
• FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR
• Efficacy and Safety of Increased Dose of TA-650 (Infliximab) in Patients With Crohn's Disease (CD)
• Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy
• Zoledronate for Osteopenia in Pediatric Crohn's
• Efficacy of Infliximab in the Treatment of Patients Affected by Corticodependent Crohn's Disease (P02732)
• Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of ITF2357 on Mucosal Healing in Patients With Moderate-to-severe Active Crohn's Disease
• Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease
• An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
• Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
• Pilot Comparative Bioavailability Study of 6Mercaptopurine (Delayed Release vs. Purinethol) in Crohns Disease Patients
• Evaluation of the Pharmacokinetics of Metronidazole 10% Ointment Applied Peri Anally in Healthy Volunteers and Patients With Perianal Crohn's Disease
• A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy
• Effect of Increlex® on Children With Crohn Disease
• Extension Study of Semapimod 60 mg IV x 3 Days
• Long-term Study of Semapimod (CNI-1493) for Treatment of Crohn's Disease
• Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus Placebo
• Laquinimod Phase IIa Study in Active Crohn's Disease
• Adalimumab in Combination With Ciprofloxacin/Placebo Treatment of Perianal Fistulas in Crohn's
• A Double Blind Placebo Control Study to Assess the Safety,Tolerability and Efficacy of Copaxone in Crohn's Disease
• Thalidomide in Pediatric Inflammatory Bowel Diseases.
• The Efficacy of Low Dose Naltrexone Therapy in Children With Crohn's Disease
• CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring
• Autologous Stem Cell Transplantation for Crohn's Disease
• Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery
• Adjuvant Vitamin D With Corticosteroids in Active Crohn's Disease
• The Effects of Naltrexone on Active Crohn's Disease
• Phase II Study of HMPL-004 in Subjects With Crohn's Disease
• Phase 2 Study of the Safety and Efficacy of LDP-02 in Mildly to Moderately Active Crohn's Patients
• NI-0401 in Active Crohn's Disease
• Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease
• A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease
• EPANOVA in Crohn's Disease, Study 1
• Ciprofloxacin for the Prevention of Postoperative Endoscopic Recurrence in Crohn's Disease
• Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease
• A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
• Induction of Clinical Response Using Rifaximin in Crohn's Disease
• Pravastatin Therapy in Patients With Active Crohn's Disease: A Pilot Study
• FolateScan in Autoimmune Disease
• Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease
• Protein and Energy Metabolism in Pediatric Crohn's Disease
• Efficacy and Safety Study of D9421-C 9 mg and 15 mg Versus Placebo in Japanese Patients With Active Crohn's Disease
• Stop Infliximab in Patients With Crohn's Disease
• Top Down Versus Step Up Strategies in Crohn's Disease
• Early Immunosuppressants in Crohn's Disease
• Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease
• Placebo Controlled Study of 3 Doses of Rifaximin-EIR Tablet to Treat Moderate, Active Crohn's Disease
• Cost-effectiveness of TPMT Pharmacogenetics
• Treatment of Crohn's Disease With an Antibiotic Regimen Directed Against Mycobacterium Avium Paratuberculosis
• Growth Hormone in Children With Juvenile Rheumatoid Arthritis (JRA) and With Crohn's Disease
• Evaluation of Topical 10% Metronidazole Ointment for the Treatment of Active Perianal Crohn's Disease
• High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease in Children
• Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
• An Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy
• Centocor Microarray Study of Patients
• Atorvastatin in Moderate Active Crohns Disease
• A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease
• Tumor Necrosis Factor Decreases Vitamin D Dependant Calcium Absorption
• High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease
• Phase II Study of RR110 in Patients With Active Crohn's Disease
• A Study of Abatacept in Patients With Active Crohn's Disease
• A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease
• Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas
• Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn's Disease
• Dietary Treatment of Crohn's Disease
• Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)
• Study of Sargramostim in Moderately to Severely Active Crohn's Disease
• A Dose-finding Study of OPC-6535 in Patients With Active Crohn's Disease
• Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease Who Completed Protocol CL0600-008
• A Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease
• Synbiotic Treatment in Crohn's Disease Patients
• Safety and Efficacy of Treatment With Interferon Beta-1a Rebif® in Patients With Crohn's Disease
• Oral Budesonide vs. Oral Mesalazine in Active Crohn's Disease (CD)
• Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease
• Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's Disease
• Efficacy Study of Targeted, Local Delivery of Drugs to Treat Crohn's Disease
• Effects of Growth Hormone in Chronically Ill Children
• Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease
• Beta Carotene From Natural Source for Patients With Non-Active Crohn's Disease
• An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Crohn's Disease
• An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Fistulizing Crohn's Disease
• Clarithromycin in Active Crohn's Disease
• Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease
• Visilizumab for Treatment of Perianal Fistulas in Crohn's Disease
• Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis
• A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease
• A Long-term Safety Study of Infliximab (Remicade)
• Study of Antibiotics in the Treatment of Colonic Crohn's Disease
• Treatment of Perianal Crohn's Disease, Combining Medical and Surgical Treatment.
• The Immunological and Blood Effects of STA-5326 Mesylate on Patients With Crohn's Disease
• Study Evaluating ERB-041 in Active Crohn's Disease
• The Effect on Mucosal Healing With Pentasa Sachet in Mild to Moderate Active "Drug: Crohn's Disease"
• Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease
• A Study Comparing the Acceptability of Pentasa® Sachets Versus Pentasa® Tablets in Children With Crohn´s Disease
• The RATIO: Registry of Infections and Lymphoma in Patients Treated With TNF-a Antagonists
• Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease
• A Study of the Safety and Efficacy of Infliximab (Remicade) in Subjects With Fistulizing Crohn's Disease
• A Study of the Safety and Efficacy of Infliximab (Remicade) in Pediatric Patients With Crohn's Disease
• A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Moderate to Severe Active Crohn's Disease
• Efficacy Study of Sargramostim in the Retreatment of Patients Who Have Crohn's Disease Who Have Previously Responded to Treatment With Sargramostim
• Open-label Trial of Leukine in Active Crohn's Disease
• Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease
• Safety and Efficacy Study in the Treatment of Pediatric Crohn's Disease
• Study in Patients With Crohn's Disease Who Are Steroid Dependent, Despite Previous Unsuccessful Attempts to Reduce Steroids Due to Worsening of Crohn's Disease
• Safety of Celecoxib in Patients With Crohn's Disease
• A Randomized Controlled Trial of VSL#3 for the Prevention of Endoscopic Recurrence Following Surgery for Crohn's Disease.
• The Influence of 5-Aminosalicylates on Thiopurine Metabolite Levels
• Effect of Iron and Vitamin E Supplementation on Disease Activity in Patients With Either Crohn's Disease or Ulcerative Colitis
• A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)
• Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870).
• Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease
• COMMIT (Combination Of Maintenance Methotrexate-Infliximab Trial)
• Vitamin D Treatment for Crohn´s Disease
• Study of Nitazoxanide Tablets in the Treatment of Mild to Moderate Active Crohn's Disease
• A Trial of Wellbutrin for Crohn's Disease
• Nasal Calcitonin in the Treatment of Bone Mineral Loss in Children and Adolescents With Inflammatory Bowel Disease
• VSL#3 Versus Placebo in Maintenance of Remission in Crohn's Disease
• Imuran Dosing in Crohn's Disease Study
• Trial of Growth Hormone Therapy in Pediatric Crohn's Disease
• An Efficacy and Safety Evaluation of Inflabloc Cap in the Treatment of Patients With Crohn's Disease
• Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease
• Safety and Activity Study of an Oral Medication to Treat Moderate to Severe Crohn's Disease
• Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease
• Imuran (Azathioprine) Dose-Ranging Study in Crohn's Disease
• Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC
• STA-5326 in Crohn's Disease Patients
• A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease
• Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease
• An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease
• A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease
• Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease
• Extracorporeal Photopheresis to Maintain Symptoms Remission During Steroid Withdrawal in Patients With Steroid-Dependent Crohn's Disease
• Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease
• A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease
• Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease
• Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease
• Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease
• CP-461 for the Treatment of Crohn's Disease
• Study Evaluating rhIL-11 in Active Crohn's Disease
• CNI-1493 for Treatment of Moderate to Severe Crohn's Disease
• Multicenter Trial For Patients With Acute Crohn's Disease
• Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease
• Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease
• G-CSF to Treat Crohn's Disease
• Monoclonal Antibody Treatment of Crohn's Disease
• Phase III Randomized Study of Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2) for Patients With Enterocutaneous Fistulae as a Complication of Crohn's Disease
• Controlled Trial of 4-Aminosalicylic Acid in Patients With Small Bowel Crohn's Disease